3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
28
Phase 1
15
Phase 3
5
Phase NA
4
Phase 1/2
3
Phase 2/3
2
Phase EARLY_PHASE1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
5
Head & Neck
4
Thoracic
3
Gynecologic
2
Genitourinary
2
CNS
2
Sarcoma
1
Other solid neoplasm
1
Lymphoid
1
Breast
1
Conditions
Stomach Neoplasms
1
Sarcoma
1
Rhabdomyosarcoma
1
Rectal Neoplasms
1
Pelvic Neoplasms
1
Ovarian Neoplasms
1
Mesothelioma, Malignant
1
Liposarcoma
1
Fallopian Tube Neoplasms
1
Desmoplastic Small Round Cell Tumor
1
Colonic Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
6
pembrolizumab
3
Specimen Handling
3
Radiotherapy
3
Oncolytic Virotherapy
3
Nivolumab
3
Irinotecan
3
Cyclophosphamide
3
X-Rays
2
Temozolomide
2
Etoposide
2
Doxorubicin
2
Biopsy
2
Bevacizumab
2
trastuzumab biosimilar HLX02
1
sodium thiosulfate
1
romiplostim
1
pertuzumab
1
perflutren
1
palbociclib
1
olaparib
1
niraparib
1
montelukast
1
glucarpidase
1
gamma-Glutamyl Hydrolase
1
fluorodopa F 18
1
eribulin
1
entrectinib
1
entacapone
1
cobimetinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase EARLY_PHASE1
×
Cisplatin
×
Sarcoma
×
Clear all
NCT04213794
2025-02-20
TOASTIT
Mayo Clinic
Phase EARLY_PHASE1
Terminated
2 enrolled